📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

Vir Biotechnology executive sells over $27k in company stock

Published 04/02/2024, 09:01 PM

Vir Biotechnology, Inc. (NASDAQ:VIR) has reported that EVP & Chief Technology Officer, Ann M. Hanly, executed a sale of company stock on April 1, 2024. According to the filing, Hanly sold a total of 2,711 shares of common stock at a price of $10.052 per share, resulting in a transaction value of over $27,250.

The transaction was noted as an automatic sale to cover tax withholding obligations related to the vesting of restricted stock units, as indicated in the footnotes of the filing. Following the sale, Hanly still owns 132,069 shares of Vir Biotechnology, indicating a continued significant investment in the company.

Additionally, the filing disclosed a minor holding of 11.52 shares of common stock, which are beneficially owned by Hanly's spouse for the benefit of a minor child. This detail was also included in the footnotes of the report.

Investors often monitor insider transactions as they can provide insights into executives' perspectives on the company's current valuation and future prospects. The sale by Hanly demonstrates routine financial management related to equity compensation and does not necessarily reflect a change in executive sentiment regarding the company's potential.

Vir Biotechnology, headquartered in San Francisco, California, is a biotechnology company focused on the research and development of treatments for serious infectious diseases.

InvestingPro Insights

Amidst the news of insider stock transactions at Vir Biotechnology, Inc. (NASDAQ:VIR), investors are keen to understand the company's financial health and future prospects. According to InvestingPro data, Vir Biotechnology holds a market capitalization of approximately $1.3 billion USD. Despite the challenging market conditions, the company has maintained a Price / Book ratio of 0.82 as of the last twelve months ending Q4 2023, suggesting that the stock may be undervalued relative to its assets.

One of the InvestingPro Tips for Vir Biotechnology is that the company holds more cash than debt on its balance sheet, which is a positive sign for financial stability. Additionally, three analysts have revised their earnings upwards for the upcoming period, indicating potential optimism about the company's earnings trajectory. However, it’s important to note that analysts also anticipate a sales decline in the current year and do not expect the company to be profitable this year.

With executive transactions often in the spotlight, it's crucial for investors to consider these underlying financial metrics. For those interested in a deeper dive into Vir Biotechnology's financials and future analyst projections, InvestingPro offers additional tips and insights. By using the coupon code PRONEWS24, readers can receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking access to a total of 9 detailed InvestingPro Tips for VIR at InvestingPro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.